Compare Amcor PLC (AMCR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs GeneDx Holdings Corp — how do they compare? Amcor PLC trades at $46.58 (market cap $21.92B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Amcor PLC is far larger — about 9× GeneDx Holdings Corp's market cap, and Amcor PLC pays a 5.49% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| AMCR | WGS | |
|---|---|---|
Market Cap | $21.92B | $2.44B |
Sector | Basic Materials | Technology |
52-Week High | $50.58 | $167.51 |
52-Week Low | $36.69 | $34.51 |
Enterprise Value | $37.03B | $2.48B |
Dividend Yield | 5.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $47.24, up 0.28% today, near the analyst consensus price target of $47.00. The stock exhibits a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $1.23, beating estimates, with revenue growth driven by the Berry acquisition. Net income margin stands at 3.06%, while the P/E ratio of 38.07 indicates a premium valuation. Recent news highlights strong Q4 earnings and expansion in China.
The outlook for AMCR is cautiously optimistic, supported by consistent earnings beats and strategic expansions. However, elevated valuation metrics and a high RSI pose near-term risks. Investor sentiment is positive with a 64% analyst buy rating, but margin pressures and integration risks from acquisitions warrant monitoring. The stock presents a balanced opportunity with growth catalysts tempered by valuation concerns.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
